We report here the first chemical synthesis of silodosin glucuronide, a metabolite of the α 1A -adrenoceptor antagonist silodosin, and its deuterium-labeled counterpart. As a key synthetic step, the incorporation of a glucuronosyl unit onto silodosin invariably led to either an undesired orthoester or a complex mixture under an array of standard glycosylation conditions. This problematic O-glycosylation may be attributed to the presence of multiple basic groups that could neutralize the acidic activators, decrease the nucleophilicity of a hydroxy group via hydrogen bond or even facilitate acyl migration side reactions. After elaborate tuning of reaction conditions, success was eventually achieved by using perbenzoylated d-glucuronosyl N-phenyltrifluroacetimidate (PTFA) as donor in combination with a procedure of sequential addition of TMSOTf. This protocol is potentially general for the glycosylation of other nitrogen-containing small molecule drugs.
Introduction
Silodosin (1), a potent and highly selective α 1A -adrenoceptor antagonist, is a marketed drug for the treatment of benign prostatic hyperplasia (BPH) with fewer cardiovascular side effects compared with other α-androgen receptor (AR) antagonists [1] . With respect to chemical structure, silodosin is composed of an indoline core scaffold linked with a catechol head piece and a primary alcohol tail (Scheme 1). A major metabolic pathway of silodosin is O-glucuronidation at the primary hydroxyl group via UDP-glucuronosyltransferase-2B7 (UGT2B7) to generate silodosin glucuronide (2) (Scheme 1) [2] . As a drug metabolite, glucuronide 2 is in high demand for pharmacokinetic studies and pharmacological evaluations [3] . However, quantities available from tedious isolation are insufficient, and the chemical synthesis of glucuronide 2 has not been reported to date. We present here the first synthesis of silodosin glucuronide (2) and its deuterium-labeled counterpart 3.
Results and discussion
At first sight, the chemical synthesis of glucuronides 2 and 3 seems to be very straightforward, by the coupling of a glucuronosyl selectively to the primary hydroxyl group of the silodosin moiety via a simple glycosylation (Scheme 2). However, its secondary and tertiary amines might conflict with the glycosylation because most of the activators are strong acids. Indeed, glycosyl acceptors in traditional glycosylations are either simple alcohols or protected saccharide fragments [4] . When the glycosyl acceptor is a complex multi-functionalized molecule, the glycosylation might result in the formation of side products [5, 6] . In such circumstances, elaborate screening of glycosyl donors and activators is critical to the success of glycosylation. Nevertheless, glycosylation of basic nitrogen-containing molecules has been reported in only a few examples and requires much more attention [7] . On the other hand, glycosylation with a glucuronosyl donor usually suffers from the presence of the electron-withdrawing C-6 carboxylate, which gives rise to decreased anomeric reactivity and deficient stability of the oxacarbenium intermediate [8] . We aimed to tackle the anticipated synthetic challenges with the targeted glucuronides 2 and 3.
Our synthetic plan (Scheme 2) of silodosin glucuronides 2 and 3 suggested a late-stage glycosylation of properly protected silodosin derivatives 5 employing the glucuronosyl donor 4 to construct the β-glucuronosidic linkage. Thus, silodosin derivatives 5 could be protected at the secondary amine to prevent neutralization of the acidic promotor, and the amide (CONH 2 ) group could remain free. In turn, 5 could easily be derived from the sequential coupling of fragments 6, 7 and 8 via alkylation. With the readily prepared glucuronosyl donor 10 [9] in hand, the synthesis of glucuronide 2 commenced from N-benzyloxycarbamate (Cbz) protection with commercially available silodosin (1) (Scheme 3). To our surprise, the amide (CONH 2 ) group underwent dehydration to cyanide (CN) by treating compound 1 with CbzCl in a mixed solution of THF/H 2 O, providing intermediate 9 (71%). As a cyano group can serve as a protecting group of amides, the intermediate 9 was then used for further coupling with peracetylated glucuronosyl trichloroacetimidate 10 (Scheme 3). Our first trial with the glycosylation was performed under the activation of TMSOTf (0.4 eq) at 0°C and the major product obtained was the orthoester [10] , an isoform of 11 (Entry 1, Table 1 ). Increasing the amount of TMSOTf to 1.2 eq for the coupling (Entry 2) promoted rearrangement of the orthoester, resulting in a 15% yield of desired glycoside 11. Unfortunately, a further increase of the amount of TMSOTf to 1.8 eq (Entry 3) gave rise to significant migration [11] of acetyl from the donor to the primary alcohol, and the use of BF 3 ·OEt 2 (1.5 eq) at −10°C provided acetylated compound 9 as the major product (Entry 4). Considering the acid labile property of acetyl ester, we decided to examine the benzoyl (Bz) group as a protecting group on the glycosyl donor. Thus, perbenzoylated glucuronosyl trichloroacetimidate 13 [12] was synthesized according to the literature (Scheme 3). As expected, acyl migration was eliminated by using a benzoylated donor with TMSOTf (0.3 eq) at 0°C (Entry 5). However, the reaction was still not productive due to the formation of the glycosyl amide side product through O,N-rearrangement [13] . To prevent this side reaction, we turned our attention to the donor N-phenyltrifluoroacetimidate (PTFA) [14] which is moderately reactive without generating a competing nucleophilic amide-leaving entity. Accordingly, the glucuronosyl PTFA donor 16 was synthesized from 15 [12] by sequential anomeric debenzoylation and treatment with CF 3 C(NPh)Cl/Cs 2 CO 3 (47%). We then investigated the glycosylation of acceptor 9 using 16 as a glycosylating agent. The use of TMSOTf (0.3 eq) at 0°C (Entry 6) still led to the corresponding orthoester as the major product by TLC and MS. However, when the amount of TMSOTf was increased to 0.9 eq (Entry 7), the desired glycoside 14 was obtained in an acceptable 47% yield with only a minor orthoester yield.
To avoid transformation of the cyano group to amide in the final stage, as for the coupling products 11 and 14, we protected the secondary amine of 1 with fluorenylmethyloxycarbonyl (Fmoc) (Scheme 3). The acceptor 17 was obtained in a quantitative yield by treatment with FmocCl in the presence of N,N-diisopropylethylamine (DIPEA). To further enhance the glycosylation yield, 1.2 eq of TMSOTf was utilized for the glycosylation of 16 with 17 (Entry 8) in the hope of complete conversion of the orthoester to glycoside. Indeed, the coupling delivered glycoside 18 in a moderate yield (61%), with glycal as a minor product derived from the elimination of donor 16 and slight benzoyl migration side product. To our delight, the coupling of 16 and 17 was eventually optimized to an 85% yield (Entry 9) by sequentially adding 0.9 eq and 0.3 eq of TMSOTf. Based on the observation of problematic glycosylations, we hypothesize that the side reactions are imparted by the presence of multiple basic nitrogen groups (Scheme 4) and suggest the following five points: (1) The influence of the tertiary amine is not eliminated because it cannot be protected. (2) The tertiary amine and free amide group might form a hydrogen bond network, which deactivates the primary hydroxyl group and thus favors S N 1-like orthoester formation. (3) The tertiary amine could partially neutralize the acidic promotor, preventing the rearrangement of orthoester to glycoside. (4) Due to the low reactivity of the acceptor hydroxyl group, the competing side reactions, including elimination of the oxacarbenium ion to form glycal and O,N-rearrangement to give glycosyl amide, could become major reaction pathways; however, this could be reduced by using N-phenyltrifluoroacetimidate (PTFA) as donor. (5) The tertiary amine might serve as a nucleophilic 'acyl shuttle' to promote migration of the acyl group, and this could be prevented by using the benzoylated glycosyl donor.
Having established the optimal conditions, the coupling of 16 and 17 was scaled up to gram scale to obtain a sufficient amount of 18, which was subjected to the one-pot final deprotection of Fmoc, C-6 methyl ester and O-benzoyl ester by using NaOH in a mixed solution of H 2 O, MeOH and THF (Scheme 3). Finally, reverse-phase C-18 column purification afforded silodosin glucuronide (2) in a 71% yield. The deuterium-labeled counterpart 3 was synthesized in a similar manner using optimal glycosylation conditions (Scheme 5). The deuterium-labeled aglycon 21 was synthesized starting from simple fragments. Thus, the alkylation of 2-O-(2,2,2-trifluoroethyl)catechol (6) with excess deuterium-labeled 1,2-dibromoethane 7D in the presence of K 2 CO 3 in acetone afforded the monobromide 19 (73%), which was coupled with optically pure amine 8 under basic conditions to provide 20 (64%). Subsequent deprotection of the benzoyl ester and hydrolysis of cyanide gave 21 (93%), which was then protected at the secondary amine by the Fmoc group to deliver 22. Finally, the glycosylation of 22 with the donor 16 was achieved with a high yield of 85%, and the global deprotection of 23 produced the deuteriumlabeled counterpart 3 in an 85% yield.
Conclusion
Silodosin glucuronide (2) is a major metabolite of silodosin by O-glucuronidation at the primary hydroxyl group. The first synthesis of compound 2 and its deuterium-labeled analogue 3 by late-stage glycosylation of the appropriately protected silodosin derivative with a glucuronosyl donor is reported here. In a challenging step, the coupling of the glucuronosyl compound to the primary alcohol resulted in a range of side reactions under several standard glycosylation conditions. It was proposed that the problematic glycosylations are imparted by the basic nitrogen groups, which could neutralize the acidic activators, decrease the nucleophilicity of the hydroxy group via hydrogen bonds or even facilitate acyl migration side reactions. This problem was solved by elaborate tuning of reaction parameters and conditions, and the best result (85% yield) was achieved by using perbenzoylated d-glucuronosyl N-phenyltrifluroacetimidate (PTFA) as the donor in combination with the sequential addition of 0.9 eq and 0.3 eq of TMSOTf. 
Experimental

Orthoester form of 11
Donor 10 (132 mg, 0.27 mmol) and acceptor 9 (87 mg, 0.14 mmol) were dissolved in anhydrous CH 2 Cl 2 (5 mL). Freshly activated 4-Å molecular sieves (500 mg) were added, and the mixture was stirred at room temperature for 1 h under a nitrogen atmosphere, then cooled to 0°C and treated dropwise with TMSOTf (10 μL, 0.4 eq). After stirring at 0°C for 1 h, the mixture was treated with a saturated solution of NaHCO 3 , extracted with ethyl acetate and the extract was concentrated under reduced pressure. Flash chromatography on silica gel (gradient 0-35%, ethyl acetate/hexanes) afforded an orthoester form of 11 (96 mg, 73%). 1 
Glucuronide 11
The coupling procedure described above provided compound 11 (20 mg, 15%). 
N-Phenyltrifluoroacetimidate (16)
To a solution of 15 (563 mg, 1.0 mmol) in DMF (10 mL) at 0°C was added N 2 H 4 · HOAc (230 mg, 2.5 mmol). The mixture was warmed to room temperature and stirred for 1 h, quenched with acetone and concentrated under reduced pressure. Flash chromatography on silica gel (gradient 0-35%, ethyl acetate/hexanes) afforded the 1-OH intermediate product (210 mg). This compound was dissolved in acetone (5 mL) at 0°C under nitrogen and the solution was treated with Cs 2 CO 3 (197 mg, 0.61 mmol) and CF 3 C(NPh)Cl (127 μL, 0.81 mmol). The mixture was filtered and concentrated. Flash chromatography on silica gel (gradient 0-15% ethyl acetate/hexanes) afforded 16 (251 mg, 36% for 2 steps); 1 
Glucuronide 14
Donor 16 (81 mg, 0.12 mmol) and acceptor 9 (48 mg, 0.08 mmol) were dissolved in anhydrous CH 2 Cl 2 (4 mL). Freshly activated 4-Å molecular sieves (170 mg) were added, and the mixture was stirred at room temperature for 1 h under nitrogen. The mixture was cooled to 0°C and TMSOTf (12 μL, 0.9 eq) was added dropwise. After stirring at 0°C for 1 h, the mixture was treated with a saturated solution of NaHCO 3 , extracted with ethyl acetate and the extract was concentrated under reduced pressure. Flash chromatography on silica gel (gradient 0-25%, ethyl acetate/hexanes) afforded 14 (51 mg, 47%). 
(R)-(9H-Fluoren-9-yl)methyl (1-(7-carbamoyl-1-(3-hydroxypropyl)indolin-5-yl)propan-2-yl)(2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)carbamate (17)
To a solution of 1 (100 mg, 0.20 mmol) in CH 2 Cl 2 (3 mL) was added DIEPA (105 μL, 0.60 mmol), and the mixture was stirred for 20 min at 0°C under nitrogen. Then a solution of FmocCl (63 mg, 0.24 mmol) in CH 2 Cl 2 (3 mL) was added over 20 min. The mixture was warmed to room temperature, stirred for 12 h, then concentrated and the residue was purified by flash chromatography on silica gel (gradient 0-60%, acetone/hexanes) to afford 17 (144 mg, 99%). 
Glucuronide 18
Donor 16 (202 mg, 0.29 mmol) and acceptor 17 (140 mg, 0.19 mmol) were dissolved in anhydrous CH 2 Cl 2 (10 mL). Freshly activated 4-Å molecular sieves (500 mg) were added and the mixture was stirred at room temperature for 1 h under nitrogen. The mixture was cooled to 0°C and TMSOTf (32 μL, 0.176 mmol) was added dropwise. After stirring at 0°C for 1h, additional TMSOTf (11 μL, 0.06 mmol) was added. The mixture was stirred for another 30 min, treated with a saturated solution of NaHCO 3 , extracted with ethyl acetate and the extract was concentrated under reduced pressure. Flash chromatography on silica gel (gradient 0-65%, ethyl acetate/ hexanes) afforded 18 (200 mg, 85%). 
Glucuronide 2
A solution of 18 (80 mg, 0.07 mmol) in a mixed solvent of MeOH/H 2 O (5/1, 2.6 mL) and THF (1 mL) was stirred at 0°C under nitrogen and treated with 3M NaOH (0.87 mL). The mixture was warmed to room temperature, stirred overnight, quenched with acetic acid (205 μL) and concentrated. Flash chromatography on a reversed-phase C18 column (gradient 0-70%, acetonitrile/water) afforded 2 (31 mg, 71%). 
Compound 19
To a solution of 6 (1.0 g, 5.2 mmol) and 7D (3.0 g, 15.6 mmol) in CH 3 CN (20 mL) was added K 2 CO 3 (1.44 g, 10.4 mmol) under nitrogen. The mixture was heated under reflux for 16 h, then filtered and concentrated. Flash chromatography on silica gel (gradient 0-10%, ethyl acetate/hexanes) afforded 19 (1.14 g, 73%). 
Compound 21
To a solution of 20 (118 mg, 0.20 mmol) in a mixed solvent of MeOH (3 mL) and THF (2 mL) was added NaOH (0.4 mL, 1M), and the mixture was stirred at room temperature. After completion as indicated by TLC analysis, the solvent was evaporated. The residue was diluted with water and extracted with ethyl acetate. The extract was dried over Na 2 SO 4 , filtered and concentrated to give a residue that was used for the next step without purification. The crude product was dissolved in DMSO (4 mL) at 0°C under nitrogen and treated with 5 M NaOH (121 μL) and 30% H 2 O 2 (87 μL). The mixture was warmed to room temperature, stirred for 24 h, diluted with water and extracted with ethyl acetate. The extract was dried over Na 2 SO 4 
Compound 22
To a solution of 21 (400 mg, 0.80 mmol) in CH 2 Cl 2 (12 mL) was added DIEPA (418 μL, 0.24 mmol) and the mixture was stirred at 0°C under nitrogen. Then a solution of FmocCl (224 mg, 0.84 mmol) in CH 2 Cl 2 (12 mL) was added over 20 min. The mixture was warmed to room temperature, stirred for an additional 12 h and concentrated. Flash chromatography on silica gel (gradient 0-60%, acetone/hexanes) afforded 22 (569 mg, 99%). 
Compound 23
Donor 16 (667 mg, 0.96 mmol) and acceptor 22 (464 mg, 0.643 mmol) were dissolved in anhydrous CH 2 Cl 2 (7 mL). Freshly activated 4-Å molecular sieves (500 mg) were added and the mixture was stirred at room temperature for 1 h under nitrogen. The mixture was cooled to 0°C and TMSOTf (105 μL, 0.9 eq) was added dropwise. After stirring at 0°C for 1 h, additional TMSOTf (35 μL, 0.3 eq) was added. The mixture was stirred for another 30 min, treated with a saturated solution of NaHCO3, extracted with ethyl acetate and the extract was concentrated under reduced pressure. Flash chromatography on silica gel (0-65% ethyl acetate/hexanes) afforded 23 (668 mg, 85%). 1 
